{"id":"NCT02946463","sponsor":"Alexion Pharmaceuticals, Inc.","briefTitle":"ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Na誰ve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)","officialTitle":"A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Complement Inhibitor-Na誰ve Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-12-12","primaryCompletion":"2023-02-28","completion":"2023-02-28","firstPosted":"2016-10-27","resultsPosted":"2019-02-12","lastUpdate":"2024-05-14"},"enrollment":272,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Paroxysmal Nocturnal Hemoglobinuria (PNH)"],"interventions":[{"type":"BIOLOGICAL","name":"Ravulizumab","otherNames":[]},{"type":"BIOLOGICAL","name":"Eculizumab","otherNames":[]}],"arms":[{"label":"Ravulizumab","type":"EXPERIMENTAL"},{"label":"Eculizumab","type":"ACTIVE_COMPARATOR"}],"summary":"The primary purpose of this study was to assess the noninferiority of ravulizumab compared to eculizumab in adult participants with PNH who had never been treated with a complement inhibitor (treatment-na誰ve).","primaryOutcome":{"measure":"Proportion Of Participants With Normalization Of Lactate Dehydrogenase (LDH) Levels","timeFrame":"Day 29 through Day 183","effectByArm":[{"arm":"Ravulizumab","deltaMin":0.536,"sd":null},{"arm":"Eculizumab","deltaMin":0.494,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":120,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Czechia","Estonia","France","Germany","Italy","Japan","Malaysia","Mexico","Poland","Russia","Serbia","Singapore","South Korea","Spain","Sweden","Taiwan","Thailand","Turkey (T端rkiye)","United Kingdom"]},"refs":{"pmids":["30510080","37804344","34526067","33178408","32869125","31949012"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=ALXN1210-PNH-301&amp;attachmentIdentifier=dadc661d-a7a3-4ea9-8bde-01f258a0442b&amp;fileName=ALXN1210-PNH-301-CSR_Synopsis_redacted.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":125},"commonTop":["Headache","Upper respiratory tract infection","Nasopharyngitis","Pyrexia","Arthralgia"]}}